Table 6 Immunohistochemical data and clinicopathological parameters for cases underwent interval debulking surgery
From: Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach
Group 2 N=39 | Ki 67 | CD8 | ER | |||
Low | High | Low | High | Negative | Positive | |
Lymphocytes | ||||||
 <20/HPF | 24 (72.7) | 3 (50.0) | 27 (100.0) | 0 | 16 (66.7) | 11 (73.3) |
 >20/HPF | 9 (27.3) | 3 (50.0) | 0 (0.0) | 12 (100) | 8 (33.3) | 4 (26.7) |
Test of significance | FET P=0.35 | FET P<0.001* | χ2=0.19 P=0.66 | |||
Stroma | ||||||
 <10% | 25 (75.8) | 2 (33.3) | 21 (77.8) | 6 (50) | 17 (70.8) | 10 (66.7) |
 >10% | 8 (24.2) | 4 (66.7) | 6 (22.2) | 6 (50) | 7 (29.2) | 5 (33.3) |
Test of significance | FET P=0.06 | χ2=3.01 P=0.08 | χ2=0.08 P=0.78 | |||
Mitosis | ||||||
 <30/10HPF | 33 (100.0) | 0 (0.0) | 24 (88.9) | 9 (75) | 22 (91.7) | 11 (73.3) |
 >30/10HPF | 0 (0.0) | 6 (100) | 3 (11.1) | 3 (25) | 2 (8.3) | 4 (26.7) |
Test of significance | FET P<0.001* | FET P=0.34 | FET P=0.18 | |||
Architecture | ||||||
 SET features | 15 (45.5) | 5 (83.3) | 11 (40.7) | 9 (75) | 10 (41.7) | 10 (66.7) |
 Papillary features | 18 (54.5) | 1 (16.7) | 16 (59.3) | 3 (25) | 14 (58.3) | 5 (33.3) |
Test of significance | χ2=2.92 P=0.09 | χ2=3.9 P=0.04* | χ2=2.31 P=0.13 | |||
Treatment response | ||||||
 Regression | 7 (21.2) | 0 (0.0) | 5 (18.5) | 2 (16.7) | 4 (16.7) | 3 (20.0) |
 Progression | 26 (78.8) | 6 (100.0) | 22 (81.5) | 10 (83.3) | 20 (83.3) | 12 (80.0) |
Test of significance | χ2=1.55 P=0.21 | χ2=0.02 P=0.89 | FET P=1.0 | |||
Stage | ||||||
 I & II | 7 (21.2) | 1 (16.7) | 5 (18.5) | 3 (25) | 4 (16.7) | 4 (26.7) |
 III & IV | 26 (78.8) | 5 (83.3) | 22 (81.5) | 9 (75) | 20 (83.3) | 11 (73.3) |
Test of significance | χ2=0.06 P=0.80 | χ2=0.214 P=0.64 | FET P=0.68 | |||
Group 2 N=39 | PR | Vimentin | E-cadherin | |||
Negative | Positive | Low | High | Negative | Positive | |
Lymphocytes | ||||||
 <20/HPF | 24 (66.7) | 3 (100) | 15 (75) | 12 (63.2) | 24 (68.6) | 3 (75) |
 >20/HPF | 12 (33.3) | 0 | 5 (25) | 7 (36.8) | 11 (31.4) | 1 (25) |
Test of significance | FET P=0.23 | χ2=0.64 P=0.42 | FET P=1.0 | |||
Stroma | ||||||
 <10% | 25 (69.4) | 2 (66.7) | 14 (70) | 13 (68.4) | 23 (65.7) | 4 (100) |
 >10% | 11 (30.6) | 1 (33.3) | 6 (30) | 6 (31.6) | 12 (34.3) | 0 (0.0) |
Test of significance | FET P=1.0 | χ2=0.01 P=0.92 | FET P=0.29 | |||
Mitosis | ||||||
 <30/10HPF | 30 (83.3) | 3 (100) | 19 (95) | 14 (73.7) | 29 (82.9) | 4 (100) |
 >30/10HPF | 6 (16.7) | 0 | 1 (5) | 5 (26.3) | 6 (17.1) | 0 (0.0 |
Test of significance | FET P=1.0 | χ2=3.4 P=0.07 | FET P=1.0 | |||
Architecture | ||||||
 SET features | 19 (52.8) | 1 (33.3) | 9 (45) | 11 (57.9) | 17 (48.6) | 3 (75) |
 Papillary features | 17 (47.2) | 2 (66.7) | 11 (55) | 8 (42.1) | 18 (51.4) | 1 (25) |
Test of significance | FET P=0.61 | χ2=0.65 P=0.42 | FET P=0.61 | |||
Treatment response | ||||||
 Regression | 6 (16.7) | 1 (33.3) | 5 (25) | 2 (10.5) | 5 (14.3) | 2 (50.0) |
 Progression | 30 (83.3) | 2 (66.7) | 15 (75) | 17 (89.5) | 30 (85.7) | 2 (50.0) |
Test of significance | FET P=0.45 | χ2=1.38 P=0.239 | FET P=0.14 | |||
Stage | ||||||
 I & II | 7 (19.4) | 1 (33.3) | 5 (25) | 3 (15.8) | 7 (20.0) | 1 (25) |
 III & IV | 29 (80.6) | 2 (66.7) | 15 (75) | 16 (84.2) | 28 (80.0) | 2 (66.7) |
Test of significance | FET P=0.508 | χ2=0.507 P=0.47 | FET P=1.0 | |||